ClinicalTrials.gg
CompletedNCT06401213Updated Jan 17, 2025

A First-in-Human Safety Trial of MTX-463

A Phase 1 interventional study of MTX-463 and Placebo in Healthy, sponsored by Mediar Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-17.

Sponsored by Mediar Therapeutics · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Nov 2024, 2 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

A randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-463 administered in healthy adults.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-463 administered in healthy adults.

SAD Portion

The SAD portion of the study will consist of 4 planned dosing cohorts each comprising 8 healthy participants. The starting dose will be 4 mg/kg (Cohort 1) with subsequent planned doses of 8 mg/kg (Cohort 2), 16 mg/kg (Cohort 3), and 30 mg/kg (Cohort 4). Planned doses may be adjusted in response to the data. Additional participants and/or additional dosing cohorts may be added as needed based on the data.

Within each cohort, participants will be randomly assigned to receive MTX-463 or matched placebo. The first 2 participants (sentinel participants) within each cohort will be randomized 1:1 to receive MTX-463 or placebo on Day 1. These participants will be monitored for 24 hours, and after review of the safety data from both participants and approval by the study Investigator and Sponsor's responsible medical officer (SRMO), the additional 6 participants will be randomized to study drug (n=5 MTX-463; n=1 placebo).

Each participant will undergo assessments at specified timepoints on Days 1 through 60. End-of-Study (EOS) procedures will be completed on Day 28 or upon early termination (ET). An End-of-Follow-up (EOF) assessment of PK and ADA will be completed on Day 60.

MAD Portion

The MAD portion of the study will consist of 3 planned dosing cohorts. Each cohort will comprise 8 healthy participants (n=6 MTX-463; n=2 placebo). The starting dose will be a 6.6 mg/kg loading dose and 4 mg/kg maintenance doses (Cohort 1) with subsequent planned doses of a 13 mg/kg loading dose and 8 mg/kg maintenance doses (Cohort 2), and a 27 mg/kg loading dose and 16 mg/kg maintenance doses (Cohort 3). Planned doses may be adjusted in response to the data. Additional participants and/or additional dosing cohorts may be added as needed based on the data.

On Day 1, participants will be randomized to receive either MTX-463 or matched placebo. The randomized participants will receive a single loading dose on Day 1 followed by 2 maintenance doses of study drug on Day 8 and Day 22. Participants will be housed inpatient from Day -1 through post-dose observation on Day 8 and from Day 21 through assessments on Day 29. All other visits will be conducted in the outpatient setting. Each participant will undergo assessments at specified timepoints on Days 1 through 82. End-of-study procedures will be completed on Day 50, or upon ET. An EOF assessment of PK and ADA will be completed on Day 82.

Safety and tolerability of MTX-463 will be reviewed through Day 29 by the study Investigator and SRMO to inform dose escalation decisions for the next dose cohort.

Additional cohorts for the SAD and MAD portions of the study may be added as needed to potentially explore lower doses.

02

Conditions studied

  • Healthy

Keywords

  • HEALTHY VOLUNTEER
  • SAD
  • MAD
  • MTX-463-I101
  • MTX-463
  • WISP-1
  • ADULT
03

In context

Lead sponsor

Mediar Therapeutics is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • All genders, ages 18 to 60 years, inclusive
  • Willing and able to complete all protocol-required study visits and procedures
  • Non-smoker and has not used nicotine- or cotinine-containing products (including tobacco, nicotine gum, patches, and e-cigarettes) for at least 90 days before Screening and until the last study visit
  • Willing to refrain from marijuana- or cannabinol-containing products for 90 days before Screening and until the last study visit
  • Willing to refrain from ingestion of alcohol from 7 days before Screening until the last study visit
  • Agree to a highly effective method of for 28 days prior to the first dose of study drug, and persist through 28 days after the last dose of study drug

Key Exclusion Criteria:

    • Any history of lung disease as determined by the Investigator, including but not limited to asthma, , pulmonary fibrosis, pulmonary embolus, or pulmonary arterial hypertension
  • Any other concurrent active medical condition determined clinically significant by the Investigator
  • (BMI) >40 kg/m2
  • Use of any systemic medications, medications to treat diabetes, antipsychotics, anticoagulants, or other medications within 90 days of Screening
  • Cancer or a history of cancer or lymphoproliferative disorder within 5 years of Screening other than adequately treated non-melanomatous skin cancers or cervical carcinoma in situ
  • Current infection with , , or (HIV) as evidenced by a positive hepatitis B-surface antigen or a positive HIV test at Screening
  • Currently pregnant, lactating, or planning to conceive or contribute to pregnancy during the trial and up to 28 days after the participant's last dose of study drug, if applicable
  • History of severe depression, psychosis, or suicidal ideation within 5 years of Screening
  • History of substance use disorder as specified in , Fifth Edition, within 1 year of Screening
  • Any clinically significant disease or laboratory abnormality detected at Screening that might interfere with a participant's ability to complete the study, on-study evaluations, or participant safety
  • Any surgical procedure, including planned procedures within 12 weeks of Screening
  • Participation in another research study of an agent within 30 days of Screening or 5 half-lives of the agent, whichever is longer
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    MTX-463

    Biological: MTX-463

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • BiologicalMTX-463

    MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases and malignancies.

  • OtherPlacebo

    Matching Placebo-- Normal Saline

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Related Adverse Events in healthy volunteers

    Clinical Safety Labs are collected, and Adverse Events are assessed in both inpatient and outpatient clinic visits

    Time frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)

  2. MTX-463 PK by dose will be evaluated for Cmax, as feasible

    Blood serum samples will be collected at protocol-specified timepoints throughout the study

    Time frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)

  3. Serum sample results will be summarized for presence of Anti-Drug Antibodies during the SAD and MAD portions of the study.

    Blood serum samples will be collected at protocol-specified timepoints throughout the study to assess for the presence and titer (if applicable) of Anti-Drug Antibodies.

    Time frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)

  4. MTX-463 PK by dose will be evaluated for AUC0-t, as feasible.

    Blood serum samples will be collected at protocol-specified timepoints throughout the study

    Time frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)

  5. MTX-463 PK by dose will be evaluated for AUC0-tau (MAD only), as feasible

    Blood serum samples will be collected at protocol-specified timepoints throughout the study

    Time frame: Through Day 82 (MAD Cohort)

  6. MTX-463 PK by dose will be evaluated for AUC0-∞, as feasible

    Blood serum samples will be collected at protocol-specified timepoints throughout the study

    Time frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)

Secondary outcomes

  1. Blood serum samples will be collected to determine the level of WISP1 engagement of MTX-463 in healthy adult participants

    These assessments will be summarized as: * Change from Baseline in total WISP1 levels * Change from Baseline in free WISP1 levels

    Time frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)

  2. To assess the effect of baseline body mass index (BMI) on total and free WISP1 levels

    Baseline levels and change from Baseline of the total and free WISP1 levels will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.

    Time frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)

Other outcomes

  1. To assess the effect of MTX-463 on PD biomarker PRO-C3 for fibrosis in healthy adult participants

    Change from Baseline in fibrosis biomarker PRO-C3 will be evaluated.

    Time frame: Through Day 36 (MAD Cohort)

  2. To assess the effect of MTX-463 on PD biomarker PRO-C6 for fibrosis in healthy adult participants

    Change from Baseline in fibrosis biomarker PRO-C6 will be evaluated.

    Time frame: Through Day 36 (MAD Cohort)

  3. To assess the effect of MTX-463 on PD biomarker C7M for fibrosis in healthy adult participants

    Change from Baseline in fibrosis biomarker C7M will be evaluated.

    Time frame: Through Day 36 (MAD Cohort)

  4. To assess the effect of baseline BMI on PD biomarker IFN-γ for inflammation

    Baseline levels and change from Baseline of PD biomarker IFN-γ for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.

    Time frame: Through Day 36 (MAD Cohort)

  5. To assess the effect of baseline BMI on PD biomarker IL-1β for inflammation

    Baseline levels and change from Baseline of PD biomarker IL-1β for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.

    Time frame: Through Day 36 (MAD Cohort)

  6. To assess the effect of baseline BMI on PD biomarker IL-2 for inflammation

    Baseline levels and change from Baseline of PD biomarker IL-2 for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.

    Time frame: Through Day 36 (MAD Cohort)

  7. To assess the effect of baseline BMI on PD biomarker IL-4 for inflammation

    Baseline levels and change from Baseline of PD biomarker IL-4 for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.

    Time frame: Through Day 36 (MAD Cohort)

  8. To assess the effect of baseline BMI on PD biomarker IL-6 for inflammation

    Baseline levels and change from Baseline of PD biomarker IL-6 for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.

    Time frame: Through Day 36 (MAD Cohort)

  9. To assess the effect of baseline BMI on PD biomarker IL-10 for inflammation

    Baseline levels and change from Baseline of PD biomarker IL-10 for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.

    Time frame: Through Day 36 (MAD Cohort)

  10. To assess the effect of baseline BMI on PD biomarker IL-12p70 for inflammation

    Baseline levels and change from Baseline of PD biomarker IL-12p70 for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.

    Time frame: Through Day 36 (MAD Cohort)

  11. To assess the effect of baseline BMI on PD biomarker IL-17A for inflammation

    Baseline levels and change from Baseline of PD biomarker IL-17A for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.

    Time frame: Through Day 36 (MAD Cohort)

  12. To assess the effect of baseline BMI on PD biomarker TNF-α for inflammation

    Baseline levels and change from Baseline of PD biomarker TNF-α for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.

    Time frame: Through Day 36 (MAD Cohort)

  13. To assess the effect of MTX-463 on PD biomarker IFN-γ for inflammation in healthy adult participants

    Change from Baseline in pro-inflammatory biomarker IFN-γ will be evaluated.

    Time frame: Through Day 36 (MAD Cohort)

  14. To assess the effect of MTX-463 on PD biomarker IL-1β for inflammation in healthy adult participants

    Change from Baseline in pro-inflammatory biomarker IL-1β will be evaluated.

    Time frame: Through Day 36 (MAD Cohort)

  15. To assess the effect of MTX-463 on PD biomarker IL-2 for inflammation in healthy adult participants

    Change from Baseline in pro-inflammatory biomarker IL-2 will be evaluated.

    Time frame: Through Day 36 (MAD Cohort)

  16. To assess the effect of MTX-463 on PD biomarker IL-4 for inflammation in healthy adult participants

    Change from Baseline in pro-inflammatory biomarker IL-4 will be evaluated.

    Time frame: Through Day 36 (MAD Cohort)

  17. To assess the effect of MTX-463 on PD biomarker IL-6 for inflammation in healthy adult participants

    Change from Baseline in pro-inflammatory biomarker IL-6 will be evaluated.

    Time frame: Through Day 36 (MAD Cohort)

  18. To assess the effect of MTX-463 on PD biomarker IL-10 for inflammation in healthy adult participants

    Change from Baseline in pro-inflammatory biomarker IL-10 will be evaluated.

    Time frame: Through Day 36 (MAD Cohort)

  19. To assess the effect of MTX-463 on PD biomarker IL-12p70 for inflammation in healthy adult participants

    Change from Baseline in pro-inflammatory biomarker IL-12p70 will be evaluated.

    Time frame: Through Day 36 (MAD Cohort)

  20. To assess the effect of MTX-463 on PD biomarker IL-17A for inflammation in healthy adult participants

    Change from Baseline in pro-inflammatory biomarker IL-17A will be evaluated.

    Time frame: Through Day 36 (MAD Cohort)

  21. To assess the effect of MTX-463 on PD biomarker TNF-α for inflammation in healthy adult participants

    Change from Baseline in pro-inflammatory biomarker TNF-α will be evaluated.

    Time frame: Through Day 36 (MAD Cohort)

  22. To assess the effect of baseline BMI on PD biomarker PRO-C3 for fibrosis

    Baseline levels and change from Baseline of PD biomarker PRO-C3 for fibrosis will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.

    Time frame: Through Day 36 (MAD Cohort)

  23. To assess the effect of baseline BMI on PD biomarker PRO-C6 for fibrosis

    Baseline levels and change from Baseline of PD biomarker PRO-C6 for fibrosis will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.

    Time frame: Through Day 36 (MAD Cohort)

  24. To assess the effect of baseline BMI on PD biomarker C7M for fibrosis

    Baseline levels and change from Baseline of PD biomarker C7M for fibrosis will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.

    Time frame: Through Day 36 (MAD Cohort)

07

Study locations

1 site
  • ICON
    Salt Lake City, Utah 84124, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in Nov 2024, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2024
First posted
May 6, 2024
StartActual
Apr 15, 2024
Primary completionActual
Nov 15, 2024
CompletionActual
Nov 15, 2024
Last update
Jan 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06401213
Lead sponsor
Mediar Therapeutics
Collaborators
ICON plc
Responsible party
Sponsor
First posted
May 6, 2024
Start date
Apr 15, 2024
Primary completion
Nov 15, 2024
Completion
Nov 15, 2024
Last update
Jan 17, 2025

Study contacts

Ahad Sabet, MD
principal investigator · ICON plc
Jeffrey Bornstein, MD
study director · Mediar Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MTX-463

Start the discussion